News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 678 results
January 2015
-
Media ReleaseNovartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis- Offering a new treatment option for patients,…
-
Media ReleaseNovartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients
December 2014
-
Media ReleaseNovartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorderAcromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1)Signifor LAR, a next-generation somatostatin analog, provides a new option…
-
Media ReleaseNovartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media ReleaseNovartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media ReleaseNovartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1]- Additionally, sustained remissions were achieved up…
-
Media ReleaseNovartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
November 2014
-
Media ReleaseNine new analyses show Novartis' LCZ696 could change course of heart failure for patients- New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus…
-
Media ReleaseNine new analyses show Novartis' LCZ696 could change course of heart failure for patients
-
Media ReleaseNovartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies-…
-
Media ReleaseNovartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
-
Media ReleaseNovartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies- Exploratory analyses showed…
Pagination
- ‹ Previous page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- …
- 57
- › Next page